Functional Contrast-Enhanced CT For Evaluation of Acute Ischemic Stroke Does Not Increase the Risk of Contrast-Induced Nephropathy

**BACKGROUND AND PURPOSE:** Concerns have recently grown regarding the safety of iodinated contrast agents used for CTA and CTP imaging. We tested whether the incidence of AN, defined by a ≥25% increase in the post-contrast scan creatinine level, was higher among patients with ischemic stroke who underwent a functional contrast-enhanced CT protocol compared with those who had no iodinated contrast administration.

**MATERIALS AND METHODS:** The contrast-exposed group consisted of 575 patients with acute ischemic stroke who underwent CTA (n = 313), CTA/CTP (n = 224), or CTA/CTP followed by conventional angiography (n = 38) within 24 hours of stroke onset and were consecutively enrolled in a prospective cohort study. The nonexposed group consisted of 343 patients with ischemic stroke, consecutively admitted to the same institution, who did not receive iodinated contrast material. Patients were stratified by baseline eGFR. In the primary analysis, the Fisher exact test was used to compare the incidence of AN between the contrast-exposed and the nonexposed patients at 24, 48, and 72 hours and on a cumulative basis. A secondary analysis compared the incidence of AN in patients who underwent conventional angiography following CTA/CTP versus patients who underwent CTA/CTP only.

**RESULTS:** The incidence of AN was 5% in the exposed and 10% in the nonexposed group (P = .003). Patients who underwent conventional angiography after contrast CT were at no greater risk of AN than patients who underwent CTA/CTP alone (26 patients, 5%; and 2 patients, 5%, respectively; P = .7).

**CONCLUSIONS:** Administration of a contrast-enhanced CT protocol involving CTA/CTP and conventional angiography in selected patients does not appear to increase the incidence of CIN.

**ABBREVIATIONS:** AN = acute nephropathy; CIN = contrast-induced nephropathy; Cr = creatinine; CTA = CT angiography; CTP = CT perfusion; eGFR = estimated glomerular filtration rate; IQR = interquartile range; kVp = kilovolt (peak); NIH = National Institutes of Health; STOP = Screening Technology and Outcomes Project in Stroke

---

**PATIENT SAFETY**

F.O. Lima
M.H. Lev
R.A. Levy
G.S. Silva
M. Ebril
É.C. de Camargo
S. Pomerantz
A.B. Singhal
D.M. Greer
H. Ay
R. Gilberto González
W.J. Koroshetz
W.S. Smith
K.L. Furie

Received July 3, 2009; accepted after revision September 4.

From the Department of Neurology, (F.O.L., G.S.S., A.B.S., É.C.d.C., D.M.G., H.A., K.L.F.), Stroke Service, Department of Radiology (M.H.L., S.P., R.G.G.), and Department of Neurology, (D.M.G.), Neurocritical Care Service, Massachusetts General Hospital, Boston, Massachusetts; Harvard University (R.A.L.), Cambridge, Massachusetts; Tufts Medical School (M.E.), Boston, Massachusetts; Department of Radiology (H.A.), Martinos Center for Biomedical Imaging, Boston, Massachusetts; National Institute of Neurological Disorders and Stroke (W.J.K.), Bethesda, Maryland; and Department of Neurology (W.S.S.), University of California, San Francisco, San Francisco, California.

Dr. Ay receives grant support from the NIH grant 1-R01-N5059710-01A2. Dr. Singhal receives grant support from the NIH grant R01-N5051412. This work was also supported by the Agency for Healthcare Research and Quality R01 HS011392, NIH P50 NS051343, the American Heart Association-Bugher Foundation, and the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. We recognize the generous support of the Esther U. Sharp Fund, the Conway Fellowship Fund, the Lakeside Fund, and the Levitt Fund.

Please address correspondence to Fabrício Oliveira Lima, MD, J. P. Kistler Stroke Research Center, Massachusetts General Hospital, 175 Cambridge St, Suite 300, Boston MA, 02114; e-mail: flima@partners.org

DOI 10.3174/ajnr.A1927

---

Multimodality imaging with MR imaging and CT technology is increasingly being used to aid in the diagnosis and treatment of acute stroke. The advantages of CT over MR imaging include its rapid accessibility, lower costs, shorter scanning-time intervals, and better patient tolerability. CTA can rapidly and noninvasively identify intra- and extracranial vascular stenoses or occlusions.1,2 CTP complements the angio-
tialized patients. In a recent study, Newhouse et al. found that 27% of hospitalized patients with baseline creatinine values between 0.6 and 1.2 mg/dL and 16% of those with baseline creatinine values >2.0 mg/dL met the definition of having CIN (a 25% increase in creatinine compared with baseline level) without receiving contrast.

On the basis of these facts, we sought to test whether the incidence of AN was higher among patients with ischemic stroke who underwent CTA, CTP, and conventional angiography compared with those who had no iodinated-contrast-agent administered.

Materials and Methods

Study Population

The contrast-exposed group consisted of 575 consecutive patients with acute (<24 hours from stroke presentation) ischemic stroke enrolled in a prospective cohort study (STOPStroke) at a single academic medical center between March 2003 and June 2005. STOP-Stroke is an observational study to evaluate the utility of emergency CT/CTA/CTP in patients admitted with suspected acute ischemic stroke. The nonexposed group consisted of 343 consecutive patients with ischemic stroke who did not receive iodinated contrast media for tests or procedures such as CTA and intra-arterial thrombolysis, consecutively presenting to the same institution between September 1999 and June 2000 or between March 2003 and November 2004. Patients already on dialysis treatment were excluded from the study. The study was approved by the institutional review board. Patients provided informed consent for the collection of data.

Neuroimaging Protocol

Nonenhanced CT and CTA acquisitions were performed according to standard departmental protocols with 8- or 16-section multidetector CT scanners (LightSpeed; GE Healthcare, Milwaukee, Wisconsin). Nonenhanced CT was performed in the transverse plane with the patient in a head holder. Representative sample parameters, with minimal variations between scanners shown as ranges, were as follows: 120–40 kVp, 170 mA, 2-second scanning time, and 5-mm section thickness. Imaging with these parameters was immediately followed by biphasic helical scanning, performed at the same head tilt as nonenhanced CT. CTA was performed after a 25-second delay (40 seconds for patients in atrial fibrillation) and administration of a nonionic contrast agent at an injection rate of 3 mL/s by using a power injector (Medrad Power Injector; Medrad, Indianola, Pennsylvania) via an 18-gauge intravenous catheter. Parameters were 140 kVp, 220–250 mA, 0.8- to 1.0-second rotation time, 2.5-mm section thickness, 1.25-mm reconstruction intervals, 3.75 mm per rotation table speed, and 0.75:1 pitch. Images were obtained from the C6 vertebral body level through the circle of Willis. Immediately afterward, a second set of images was obtained from the aortic arch to the skull base. Afterward, source images were reconstructed into standardized maximum-intensity-projection views of the intracranial and extracranial vasculature.

CTP was initiated 5 seconds after the administration of contrast at 7 mL/s. Four contiguous CT sections were acquired simultaneously every second, during 45–60 seconds. Scanning sections were 5-mm thick. Postprocessing of cerebral blood flow and cerebral blood volume maps was done by using commercially available software (CT Perfusion 3; GE Healthcare). CTA/CTP was the standard protocol for patients with stroke considered within the window for reperfusion therapies (<12 hours from stroke-symptom onset). In the 12- to 24-hour window, the decision as to whether to perform CTA or CTA/CTP was based on clinician preference.

Contrast Agent and Procedures

All patients in the contrast-exposed group received the nonionic iodinated contrast agent iopamidol (Isovue; Bracco Diagnostics, Princeton, New Jersey) at a dose range from 100 (CTA alone; 313 patients, 34%) to 140 mL (CTA and CTP; 224 patients, 39%). Some patients also underwent transfemoral angiography for intra-arterial thrombolysis after the CTA/CTP (38 patients, 7%), receiving a larger dose of contrast agent (approximately 230 mL total). The clinical institutional protocol recommends hydration and pretreatment with N-acetylcysteine in patients considered at “high risk” for contrast-induced nephropathy (eg, patients with diabetes, baseline creatinine level >1.9 mg/dL). Patients in the nonexposed group did not receive iodinated contrast agents.

Patient age, sex, race, and medical history, including diabetes, hypertension, congestive heart failure, and coronary artery disease were collected on all patients through interviews, prospective clinical examinations, and review of the medical records by trained staff. Arterial hypertension was defined as a positive history or antihypertensive treatment. Diabetes mellitus was defined as a positive history or the presence of oral hypoglycemic medication or insulin treatment. Congestive heart failure was defined as a previous positive clinical diagnosis with episodes of dyspnea requiring emergency treatment or inpatient treatment or appropriate medical treatment. Coronary artery disease was defined by a history of myocardial infarction, typical or atypical angina, electrocardiogram evidence of old myocardial infarction, or a history of a cardiac revascularization procedure. All serum creatinine values available at baseline (admission or pre-CTA) and at 24, 48, and 72 hours after the admission were recorded. The eGFR was calculated with the Modification of Diet in Renal Disease Study equation by using the admission creatinine value. The term “contrast-induced nephropathy” cannot be applied to patients who did not receive contrast agents and implies causality. Therefore, the term “AN” was used to define a ≥25% increase in creatinine from baseline level within 3 days.

Baseline renal dysfunction is an important predictor of a subsequent increase in creatinine levels. To control for baseline renal function, we performed a stratified analysis based on admission eGFR (≥60 mL/min/1.73 m², 30–59 mL/min/1.73 m², and <30 mL/min/1.73 m²), according to guidelines of the National Kidney Foundation for classification of chronic kidney disease.

Statistical Analysis

All statistical analysis was performed by using SPSS software, Version 16.0 (SPSS, Chicago, Illinois). Age, Cr level, and eGFR were analyzed as continuous variables. Data are reported as mean ± SD or median ± IQR for continuous variables and as frequency for categoric variables. Differences in age between contrast-exposed and nonexposed groups were compared by using the independent-samples t test. Differences in Cr level and e-GFR between contrast-exposed and nonexposed groups were compared by using the Mann-Whitney U test. Differences in sex, race, and previous history of hypertension, diabetes, congestive heart failure, and coronary artery disease were assessed by the Fisher exact test. For the primary analysis, all patients who received iodinated contrast agent (including CTA, CTA/CTP, and CTA/CTP plus conventional angiography) were classified under the
Table 1: Baseline characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Study Population (N = 518)</th>
<th>Contrast-Exposed (N = 575)</th>
<th>Nonexposed (N = 343)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (yr)</td>
<td>68 ± 15</td>
<td>67 ± 15</td>
<td>70 ± 14</td>
<td>.005a</td>
</tr>
<tr>
<td>Sex, % women</td>
<td>48%</td>
<td>48%</td>
<td>48%</td>
<td>1.0b</td>
</tr>
<tr>
<td>Race, % white</td>
<td>92%</td>
<td>93%</td>
<td>91%</td>
<td>.9b</td>
</tr>
<tr>
<td>Hypertension</td>
<td>60%</td>
<td>59%</td>
<td>62%</td>
<td>.5b</td>
</tr>
<tr>
<td>Diabetes</td>
<td>19%</td>
<td>17%</td>
<td>24%</td>
<td>.006b</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>8%</td>
<td>6%</td>
<td>10%</td>
<td>.03b</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>23%</td>
<td>22%</td>
<td>24%</td>
<td>.7</td>
</tr>
<tr>
<td>Admission Cr (mg/dL), median</td>
<td>1.07 (0.8–1.2)</td>
<td>1.0 (0.8–1.1)</td>
<td>1.2 (0.8–1.4)</td>
<td>&lt;.001c</td>
</tr>
<tr>
<td>Admission eGFR (mL/min/1.73 m²), median</td>
<td>73 (56–88)</td>
<td>76 (61–89)</td>
<td>68 (47–87)</td>
<td>&lt;.001c</td>
</tr>
</tbody>
</table>

a Student t test.
b Fisher exact test.
c Mann-Whitney U test.

The overall incidence of AN was 7% (63 patients). The incidence of AN in contrast-exposed patients was 5% (28 subjects), which was lower than the 10% incidence (35 subjects) in the nonexposed group (P = .002). Significantly higher incidences of AN were noted in the nonexposed group at 24 and 48 hours, but these were not significantly different by 72 hours (Table 2). In the multivariate regression model, after adjusting for age, sex, admission eGFR, hypertension, diabetes, coronary artery disease, and congestive heart failure, patients in the contrast-exposed group presented a lower risk for developing AN than patients in the nonexposed group (odds ratio, 0.42; 95% confidence interval, 0.24–0.71).

Thirty-eight patients underwent conventional angiography following the contrast-enhanced CT. The patients who underwent angiography did not differ significantly from the patients who underwent CTA and/or CTP alone on the basis of age (67 ± 17 years versus 65 ± 15 years, P = .8), sex (53% women versus 47% women, P = .5), race (92% white versus 93% white, P = .7), hypertension (67% versus 58%, P = .4), diabetes (21% versus 16%, P = .4), congestive heart failure (10% versus 2%, P = .2), coronary artery disease (32% versus 22%, P = .2), baseline creatinine level (0.9 mg/dL; IQR, 0.8–1.2 versus 1.0 mg/dL; IQR, 0.9–1.1; P = .9) or eGFR (72 mL/min/1.73 m²; IQR, 63–84 versus 76 mL/min/1.73 m²; IQR, 60–90), respectively. The overall incidence of AN in both groups was 5% (P = .7). The incidence of AN at 24, 48, and 72 hours did not differ between the angiography and the CTA/CTP only group.
Discussion
This is the largest reported retrospective cohort study examining the risk of contrast-induced nephropathy in patients with acute stroke. We found that the incidence of AN in the contrast-exposed group did not exceed the incidence of AN in the nonexposed group. In fact, after adjusting for possible confounders, the contrast-exposed group had a lower risk for developing AN than the nonexposed group. The addition of contrast used for conventional angiography after CTA/CTP did not increase the incidence of AN.

Contrast-induced nephropathy is the third most common cause of renal failure, accounting for 11% of cases of hospital-acquired renal insufficiency. The most commonly accepted definition of CIN is an increase in creatinine of ≥25% of the baseline value or an absolute increase of ≥0.5 mg/dl in creatinine above the baseline value within 48–72 hours of exposure to contrast material. Serum creatinine level typically peaks 3–5 days after contrast administration and returns to baseline within 1–3 weeks. Several conditions increase the risk for CIN. Pre-existing renal disease with an elevated level of serum creatinine is the primary risk factor for developing CIN. A baseline test of renal function is strongly recommended by the American College of Radiology and European Association of Uroradiologists as a way to assess the risk of CIN.

Expanded use of CT-based multimodal imaging has been constrained by concerns about potential nephrotoxicity, particularly because time pressures in evaluating patients with acute stroke can necessitate making decisions regarding contrast administration in the absence of a baseline creatinine value. Smith et al demonstrated that waiting for the baseline creatinine level resulted in lengthy delays (average time, 73.3 ± 51 minutes) in patients with acute stroke. Because acute stroke management protocols seek to minimize the time from symptom onset to thrombolytic delivery, any delay in the process of evaluation is detrimental. This study supports the safety of intravenous contrast agents in patients with acute stroke independent of baseline eGFR when standard prophylactic measures are taken (including the use of low-osmolar contrast agents, adequate intravenous hydration, and pretreatment with N-acetylcysteine in high-risk patients).

A combination of several mechanisms is thought to be responsible for the development of CIN. Renal vasoconstriction and direct tubular injury are thought to be the main factors. The medullary portions of the kidney are particularly vulnerable to reductions in blood flow, given the long length of the vasa recta, the low levels of partial pressure of oxygen encountered, and the high oxygen requirements of the renal tubules responsible for salt reabsorption. Direct tubular injury by contrast agents may be exacerbated by renal vasoconstriction. The incidence of CIN might have been overestimated by extrapolating data from cardiology patients who underwent conventional angiography. Local renal hypoxia may be aggravated by other complications frequently found in this population of patients, such as transient reduced cardiac output and perturbations in the pulmonary ventilation-perfusion relationship.

Our data are consistent with the low rates of CIN reported after CTA/CTP in patients with stroke. The incidence of CIN might have been overestimated in previous studies though. As many as 27% of hospitalized patients with baseline creatinine values between 0.6 and 1.2 mg/dL and 16% of those with baseline creatinine values of ≥2.0 mg/dL would be included under the definition of CIN (a 25% increase in creatinine compared with baseline level) without receiving contrast material. Very few studies have used control groups to compare the risk of AN in patients receiving and not receiving iodinated contrast.

Pre-existing renal dysfunction is the most important risk factor for the development of CIN. Although an elevated baseline creatinine level is a marker of pre-existing nephropathy, it is not reliable enough to identify patients at risk for CIN. Creatinine clearance is the most reliable way to evaluate renal function. Its estimation can be easily performed by using the Modification of Diet in Renal Disease Equation. The risk of CIN increases as the eGFR falls, particularly below 60 mL/min/1.73 m². Our study is the first retrospective cohort study to stratify on the basis of baseline renal function.

There are limitations to our study. Patients undergoing the CTA/CTP were highly selected, as evidenced by the higher rates of diabetes, congestive heart failure, and renal insufficiency in the control population. We believe that this recapitulates routine clinical practice, however. We did not collect data on compliance with recommendations for renal protection after contrast administration (including intravenous hydration and pretreatment with N-acetylcysteine), though given the acute nature of the studies, hydration was likely the only potential intervention. Because of the low number of cases, the results are not generalizable to patients with severe renal insufficiency (eGFR <30).

Conclusions
Although, to our knowledge, it is yet to be established that acute CTA and CTP imaging improve stroke outcomes, they are commonly used in evaluating patients with stroke. This study provides additional evidence that contrast administration does not increase the risk of nephrotoxicity, provided standard prophylactic measures are taken.

Acknowledgments
We sincerely thank the patients who participated and members of the Massachusetts General Hospital Stroke Service who provided invaluable support.

References
6. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: